Follow us on Twitter
This page is updated frequently with new Leukemia-related patent applications. Subscribe to the Leukemia RSS feed to automatically get the update: related Leukemia RSS feeds. RSS updates for this page: Leukemia RSS
|| List of recent Leukemia-related patents
| Combination therapy with an anti-cd19 antibody and a purine analog|
The present disclosure describes a pharmaceutical combination of an anti-cd19 antibody and a purine analog for the treatment of non-hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.. .
| Humanized anti-hla-dr antibodies|
The present invention concerns compositions and methods of use of humanized anti-hla-dr antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing cdc or adcc.
|Quantitative multiplex methylation-specific pcr|
Methods are provided for diagnosing in a subject a condition, such as a carcinoma, sarcoma or leukemia, associated with hypermethylation of genes by isolating the genes from tissue containing as few as 50 to 1000 tumor cells. Using quantitative multiplex methylation specific pcr (qm-msp), multiple genes can be quantitatively evaluated from samples usually yielding sufficient dna for analyses of only 1 or 2 genes.
|Methods and pharmaceutical compositions for treating lymphoid malignancy|
The present invention provides, inter alia, methods for treating, preventing, or ameliorating the effects of a lymphoid malignancy, such as those associated with a mutated phosphatase and tensin homolog (pten) gene, or t-cell acute lymphoblastic leukemia (t-all). These methods include administering to a subject an effective amount of a phosphoinositide 3-kinase-delta (pi3kδ) inhibitor and a phosphoinositide 3-kinase-gamma (pi3kγ) inhibitor.
|Heterocyclic compounds and their uses|
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
|Cardiac glycoside analogs in combination with emodin for cancer therapy|
A method and medicine for treating leukemia or other cancer includes administering to a patient diagnosed with leukemia or other cancer a treatment regimen that includes periodic doses of a combination of emodin and digoxin.. .
|Treatment of leukemia|
Compositions and methods for the treatment of leukemia by inhibiting foxo signaling are described.. .
|Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer|
Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid.
|Promyelocytic leukemia protein as a redox sensor|
The present invention relates to a method for determining the redox status of a cell or tissue comprising a step consisting of determining the level of pml nuclear bodies in said cell or tissue.. .
|Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations|
New polymorphs of 5-amino or substituted amino 1,2,3-triazole and substituted derivatives thereof, of orotates of the carboxyamidotriazoles, of formulations of the triazoles and orotic acid in the ratio of 1:1 to 1:4 (base:acid) and of safer processes of the preparation of the same are disclosed. The compounds are useful in the control and treatment of diseases including, but not limited to solid cancers, macular degeneration, retinopathy, chronic myeloid leukemia, aids and diseases which rely on aberrant signal transduction.
|Inhibitors of c-fms kinase|
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
|New natural and synthetic compounds for treating cancer and other diseases|
This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, cns, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti-adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins.
|Method for screening for compounds selectively interacting with rad9|
Natural and synthetic compounds of formulae ia-ie having a lactone structure, in particular securolide, have been determined to be effective anti-tumor compounds which target the hrad9 gene and/or protein encoded thereby or complex containing the protein and/or the p53 gene and/or protein. Securolide is cytoselective for mutants of hrad9 based on studies conducted in rad9 mutant yeast strains.
|Diagnosis and treatment of cancer using anti-itm2a antibody|
Disclosed is a monoclonal antibody binding to an itm2a protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as ewing's sarcoma, t cell leukemia, t cell lymphoma, acute myeloid leukemia, b cell tumor, and multiple myeloma.
|Therapeutic and diagnostic target|
The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of acute myeloid leukemia (aml), b-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer, for monitoring the effectiveness of acute myeloid leukemia (aml), b-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer treatment, and for drug development. The present invention also provides methods and compositions for depletion of immune cells to treat inflammatory diseases..
|Therapeutic and diagnostic target gene in acute myeloid leukemia|
Methods are provided for treating a cancer in a subject comprising administering to the subject an agent which inhibits expression of an hlx gene in the subject, or an agent which inhibits activity of an expression product of the hlx gene, and also for diagnosing a subject as likely to develop a cancer comprising determining whether a stem cell obtained from the subject expresses a hlx gene at a level in excess of predetermined control level. Kits therefor are also provided..
|Compositions and methods for inhibiting ccl3|
The present invention relates to the discovery that ccl3, through at least one of its receptors ccr1 and ccr5, plays a role in the pathologies associated with myeloid neoplasms. In various embodiments, the pathologies associated with myeloid neoplasms treatable by the compositions and methods of the invention described herein include, but are not limited to, at least one of osteoclast/osteoblast imbalance, inhibition of osteoblast function, bone loss, disregulation of the hematopoietic stem cell microenvironment, abnormal hematopoietic recovery, pancytopenia, anemia, thrombocytopenia, neutropenia, bicytopenia, and erythrocytopenia.
|Acadesine derivatives, products and compositions including same, therapuetic uses thereof, and methods for synthesizing same|
Acadesine derivatives as a drug, as well as the derivatives for the treatment of cancer and in particular for the treatment of chronic myeloid leukemia are described. Also, product containing the derivatives and at least one second active ingredient as a combination product for simultaneous, separate or sequential administration, in the treatment of cancer, as well as a pharmaceutical composition containing the derivatives and a pharmaceutically acceptable carrier are described.
|Leukemia classification using cpd data|
Embodiments of the present invention encompass automated systems and methods for predicting an acute leukemia sub-type of an individual diagnosed with acute leukemia based on a biological sample obtained from blood of the individual. Exemplary techniques involve correlating aspects of direct current (dc) impedance, radiofrequency (rf) conductivity, and/or light measurement data obtained from the biological sample with an acute leukemic sub-type of the individual..
|Methods of treating acute myeloid leukemia by blocking cd47|
Methods are provided to manipulate phagocytosis of cancer cells, including e.g. Leukemias, solid tumors including carcinomas, etc..
|Methods for manipulating phagocytosis mediated by cd47|
Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. Circulating hematopoietic cells, bone marrow cells, etc.; and solid tumor cells.
|Resorcylic acid lactone compounds|
Disclosed are a novel resorcyclic acid lactone compound with inhibitory activity against protein kinases, a pharmaceutically acceptable salt thereof, a method for the synthesis thereof, and a pharmaceutical composition for the treatment and prevention of various cancer diseases comprising the same as an active ingredient. The novel resorcyclic acid lactone compound is useful as a therapeutic for cancer diseases, especially blood cancer, inter alia, acute myeloid leukemia (aml)..
|Combination therapy with volasertib|
Disclosed is the use of volasertib or a salt or a hydrate thereof for treating patients suffering from acute myeloid leukemia (aml) comprising administering a high dose of volasertib in combination with fludarabine, cytarabine and granulocyte colony-stimulating factor (gcsf) or in combination with fludarabine, cytarabine, gcsf and a daunorubicin citrate liposome injection.. .
|Inhibitors of c-fms kinase|
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
|Compositions and methods for modulating gamma-c-cytokine activity|
The various embodiments relate to peptide antagonists of γc-family cytokines, interleukin-2 (il-2), interleukin-4 (il-4), interleukin-7 (il-7), interleukin-9 (il-9), interleukin-15 (il-15), and interleukin-21 (il-21). The γc-cytokines are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd).
|Emetine derivatives, prodrugs containing same, and methods of treating conditions using same|
Compounds are provided herein which are emetine derivatives that can be used as prodrugs which selectively undergo activation to release emetine in specific cellular conditions. In one aspect, a blocking group is incorporated onto the emetine molecule by the derivization of the n2′-position with moieties that can be selectively removed by hydrolysis in the cancer/tumor microenvironment.
|Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia|
This invention provides methods and kits for diagnosing, ascertaining the clinical course of minimal residual disease associated with acute lymphoblastic leukemia (all). Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with diseases associated with all based on patterns of surface marker expression unique to all..
|Prediction of clinical outcome in hematological malignancies using a self-renewal expression signature|
Methods, compositions, and kits are provided for providing a diagnosis, a prognosis, or a prediction of responsiveness to a therapy for a patient with a hematological malignancy. In practicing the subject methods, the expression level of at least one leukemia stem cell (lsc) genes in a tissue sample is assayed to obtain an lsc expression representation.
|Kit for detecting bovine leukemia virus(blv), and use thereof|
A kit for detecting bovine leukemia virus (blv) according to the present invention includes: a first pcr primer being oligonucleotide including successive 20 bases or more in the base sequence denoted by seq id no: 1, the first pcr primer being oligonucleotide having 50 bases or less; and second pcr primer being including successive 20 bases or more in the base sequence denoted by seq id no: 2, the second pcr primer being oligonucleotide having 50 bases or less is included.. .
|Compositions and methods for treatment of hematological malignancies|
Use of a chimeric protein selected from the group consisting of ctla4-fasl and cd40-fasl proteins for treatment of lymphoma and/or a multiple myeloma and/or a leukemia as described herein, and pharmaceutical compositions and methods of treatment thereof.. .
|Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof|
The present invention shows that human vδ1+ ncr+ t cells can be differentiated and expanded from total γδ peripheral blood lymphocytes (pbls), upon regular in vitro or ex vivo stimulation with γδtcr agonists and γc-family cytokines. This subset surprisingly expresses nkp30, nkp44 and nkp46, and high levels of granzyme b that associate with highly enhanced cytotoxicity against lymphoid leukemias..
|Feline leukemia virus trans-membrane protein p15e for diagnosis of felv infection|
The invention provides for a method for the detection of felv infection in a patient, wherein a sample obtained from the patient is contacted in-vitro with a recombinant transmembrane p15e protein in a p15 (e) antibody binding step.. .
|Crystalline forms and processes for the preparation of cannabinoid receptor modulators|
The present invention relates to crystalline forms of (1as,5as)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1h-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid ((s)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (compound 1) and pharmaceutical compositions thereof that modulate the activity of the cannabinoid cb2 receptor and are therefore useful in the treatment of cb2 receptor-mediated disorders, for example, osteoarthritis; pain; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; cns inflammation for example; atherosclerosis; undesired immune cell activity, and inflammation associated with a disorder selected from: osteoarthritis, anaphylaxis, behcet's disease, graft rejection, vasculitis, gout, spondylitis, viral disease, bacterial disease, lupus, inflammatory bowel disease, autoimmune hepatitis, and type 1 diabetes mellitus; age-related macular degeneration; cough; leukemia; lymphoma; cns tumors; prostate cancer; alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis; and parkinson's disease.. .
The present invention provides a method for treating a hyperproliferative disorder characterized by expression of a mutant form of p53 in a subject, the method comprising administering to the subject a therapeutically effective amount of an agent which inhibits promyelocytic leukemia (pml) protein.. .
|Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias|
Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as revlimid® or lenalidomide.
Popular terms: [SEARCH]
Leukemia topics: Myelogenous, Myelogenous Leukemia, Proliferative, Autoimmune, Stem Cells, Breast Cancer, Rheumatoid Arthritis, Myeloid Leukemia, Acute Myelogenous Leukemia, Lymphocytic, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia, Epigenetic, Multiple Myeloma, Polyphenol
Follow us on Twitter
This listing is a sample listing of patent applications related to Leukemia for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Leukemia with additional patents listed. Browse our RSS directory or Search for other possible listings.